93
Views
8
CrossRef citations to date
0
Altmetric
Review

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

&
Pages 2189-2201 | Published online: 02 Nov 2018

References

  • NooneAMHowladerNKrapchoMSEER Cancer statistics review, 1975–2015SEER Cancer Statistics Review Available from: https://seer.cancer.gov/statfacts/html/ovary.htmlAccessed May 21, 2018
  • BristowREMontzFJLagasseLDLeuchterRSKarlanBYSurvival impact of surgical cytoreduction in stage IV epithelial ovarian cancerGynecol Oncol199972327828710053096
  • BristowBRETomacruzRSArmstrongDKMaximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era200820512481259
  • ArmstrongDPlaxeSCAlvarezRDOvarian cancer2NCCN Clin Pract Guidel Oncol20182 Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#ovarianAccessed October 15, 2018
  • VergoteIdu BoisAAmantFHeitzFLeunenKHarterPNeoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Gynecol Oncol2013128161123006973
  • VergoteIAmantFKristensenGEhlenTReedNSCasadoAPrimary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancerEur J Cancer201147Suppl 3S88S9221944035
  • BristowREChiDSPlatinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysisGynecol Oncol200610331070107616875720
  • WagnerUMarthCLargillierRFinal overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsBr J Cancer2012107458859122836511
  • AghajanianCGoffBNycumLRWangYVHusainABlankSVFinal overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancerGynecol Oncol20151391101626271155
  • Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
  • SwisherEMLinKKOzaAMRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol2017181758727908594
  • ColemanRLOzaAMLorussoDRucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet2017390101061949196128916367
  • FarmerHMccabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
  • BryantHESchultzNThomasHDErratum: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature20074477142346918
  • CantorDThe frustrations of families: Henry Lynch, heredity, and cancer controlMed Hist200650327930216902702
  • KingMCMarksJHMandellJBNew York Breast Cancer Study GroupBreast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2Science2003302564564364614576434
  • HallJMLeeMKNewmanBLinkage of early-onset familial breast cancer to chromosome 17q21Science19902504988168416892270482
  • WoosterRBignellGLancasterJIdentification of the breast cancer susceptibility gene BRCA2Nature199537865597897928524414
  • LuKKauffNPowellBACOG practice bulletin 103: Hereditary breast and ovarian cancer syndromeObstet Gynecol200911410619220219546798
  • JavleMCurtinNJThe role of PARP in DNA repair and its therapeutic exploitationBr J Cancer201110581114112221989215
  • HelledayTThe underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandingsMol Oncol20115438739321821475
  • HollidayRA mechanism for gene conversion in fungiGenet Res196452282304
  • MirzaMRMonkBJHerrstedtJNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerN Engl J Med2016375222154216427717299
  • MeiLChenHWeiDMMaintenance chemotherapy for ovarian cancerCochrane Database Syst Rev20132728CD007414
  • PecorelliSFavalliGGadducciAPhase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the after-6 protocol 1J Clin Oncol200927284642464819704064
  • BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
  • GourleyCFriedlanderMMatulonisUAClinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)J Clin Oncol20173515 Suppl5533
  • Pujade-LauraineELedermannJASelleFOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol20171891274128428754483
  • PlummerRMiddletonMWilsonRFirst in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumorsJ Clin Oncol20052316 Suppl3065
  • DrewYMulliganEAVongWTTherapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2J Natl Cancer Inst2011103433434621183737
  • IhnenMZu EulenburgCKolarovaTTherapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMol Cancer Ther20131261002101523729402
  • ZanjirbandMCurtinNEdmondsonRJLunecJCombination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancerOncotarget2017841697796979629050241
  • KossatzSCarneyBFarleyCWeberWADrainCMReinerTDirect imaging of drug distribution and target engagement of the PARP inhibitor rucaparibJ Nucl Med20185981316132029572258
  • AlmeidaGSBawnCMGallerMPARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRSNMR Biomed2017309e3736e3738
  • MccruddenCMO’RourkeMGCherryKEVasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfPLoS One2015102e011818725689628
  • AliMTelferBAMccruddenCVasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?Clin Cancer Res200915196106611219789326
  • KristeleitRShapiroGIBurrisHAA phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumorsClin Cancer Res201723154095410628264872
  • WilsonRHEvansTJMiddletonMRA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursBr J Cancer2017116788489228222073
  • KondrashovaONguyenMShield-ArtinKSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinomaCancer Discov20177998499828588062
  • MccormickADonoghuePDixonMOvarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparibClin Cancer Res20172382050206027702817
  • OzaAMTinkerAVOakninAAntitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Gynecol Oncol2017147226727528882436
  • LiuAYCohenJGWalshCSHolschneiderCHSinnoAKA cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancerGynecol Oncol20171471196
  • MooreKColomboNScambiaGMaintenance olaparib in patients with newly diagnosed advanced ovarian cancerN Engl J Med Epub20181021